Japanese
Titleバセドウ病におけるTSH結合阻害性抗体測定の臨床的有用性に関する検討 - 抗甲状腺剤治療による変化および予後との関連について -
Subtitle原著
Authors飯田泰啓*, 小西淳二*, 高坂唯子*, 御前隆*, 中島鉄夫*, 遠藤啓吾*, 鳥塚莞爾*
Authors(kana)
Organization*京都大学医学部放射線核医学科
Journal核医学
Volume20
Number10
Page1425-1431
Year/Month1983/12
Article原著
Publisher日本核医学会
Abstract「要旨」TSHのradioreceptor assay (Smithキット) を用いて, バセドウ病におけるTSH-binding inhibitor immunoglobulins (TBII) 活性を測定し臨床的有用性を検討した. TBII活性は未治療患者35例中30例 (85.7%) に陽性であり, 甲状腺99mTcO4-摂取率と有意に正相関した (r=-0.721, p<0.01) . 抗甲状腺剤1〜2錠の維持量で6か月以上経過しT3抑制試験を行った時点では48例中12例 (25%) と陽性率が低下したが, 5年以上経過して3錠以下に減量できない難治例では26例中17例 (65.4%) が陽性であった. T3抑制陽性の21例は全例TBII活性陰性であったが, T3抑制陰性の27例では12例 (44.4%) が陽性と有意に高い検出率であった (p<0.001) . 6か月以上寛解を維持した15症例は全例投薬中止時にTBII活性が陰性であった. 投薬中止時にTBIIが陽性であった5例はすべて再発した. 再発時の陽性率は73.9%であった. このような成績よりTBII活性の測定は抗甲状腺剤治療患者の経過観察, 予後判定に際し有用な指標を与えるものと考えられた.
Practice臨床医学：一般
Keywordsradioreceptor assay, TSH-binding inhibitor immunoglobulins, Graves' disease, antithyroid drug, prognosis
English
TitleClinical Usefulness of the Assay of TSH-binding Inhibitor Immunoglobulins (TBII) in Patients with Graves' Disease : Effect of Antithyroid Drug Treatment on TBII
SubtitleOriginal Articles
AuthorsYasuhiro IIDA, Junji KONISHI, Tadako KOUSAKA, Takashi MISAKI, Tetsuo NAKAJIMA, Keigo ENDO, Kanji TORIZUKA
Authors(kana)
OrganizationDepartment of Radiology and Nuclear Medicine, Kyoto University School of Medicine
JournalThe Japanese Journal of nuclear medicine
Volume20
Number10
Page1425-1431
Year/Month1983/12
ArticleOriginal article
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary] Using a TSH-radioreceptor assay kit (B.R. Smith) , we assayed TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease before and after anti-thyroid drug treatment. In untreated patients, TBII activity was positive in 30 (85.7%) out of 35 cases. The activity decreased after anti-thyroid drug treatment. At the time of T3 suppression test after having been euthyroid for at least 6 months with maintenance doses, TBII were positive in 12 (25%) out of 48 cases. On the other hand, TBII were detectable in 30 out of 35 patients (85.7%) who had been medicated with more than 15mg of methimazole for over 5 years. All 21 patients who were T3 suppressible were negative in TBII. On the other hand, twelve out of 27 patients who were not T3 suppressible were positive in TBII activity. Thus, TBII activity was significantly associated with negative T3 suppressibility (p<0.001) . TBII had not been detected at the cessation of therapy in any of 15 patients who remained euthyroid during the follow-up period. All patients who had been positive in TBII relapsed. In 23 patients who relapsed, TBII were detectable in as high as 73.9% at the time of relapse. These data indicate that TBII are closely related to a pathogenic factor of Graves' disease and are useful in the follow-up of the patients treated with anti-thyroid drugs.
PracticeClinical medicine
Keywordsradioreceptor assay, TSH-binding inhibitor immunoglobulins, Graves' disease, antithyroid drug, prognosis

【全文PDF】